News Category
Nutriband Inc. has filed a non-provisional utility patent application with the USPTO for improved aversive formulations and coating methods for its AV...
VERAXA Biotech's adoption of FDA-aligned New Approach Methodologies could significantly reduce animal testing and accelerate the development of its an...
Nutriband Inc. celebrates its fifth anniversary on the Nasdaq Capital Market with a shareholder letter detailing the advancement of its abuse-deterren...
Helus Pharma Inc. has officially changed its legal name from Cybin Inc., a move that reflects its evolution from a clinical-stage discovery company to...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate beyond discovery, reinforcing its oncology pipeline and intellectual property ...
MindWave Innovations will build and operate FlashChain on its MindChain Layer-2 infrastructure, receiving equity and a 20% token allocation, as Apimed...
Creative Biolabs integrates glycoprotein development with glycan characterization, offering tailored analytical strategies to address glycosylation he...
Helus Pharma's shareholders approved a legal name change from Cybin Inc. and elected eight directors, signaling the company's transition from a clinic...
Nutriband Inc. (NASDAQ: NTRB) will let its outstanding warrants expire on Sept. 30, 2026, at 5 p.m. EDT without extension or repricing, a move that co...
Peptide Wholesale Supply now provides HPLC chromatographic data for each batch of BPC-157, Semaglutide, and Tirzepatide bulk orders, enhancing analyti...
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition across human and canine osteosarcoma cell lines, suggesting a potential dual-purpos...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing therapies to overcome cancer drug...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a significant milestone for a novel myelin-repair approach in multiple sclerosis, p...
Nutriband's receipt of a USPTO Notice of Publication for trademarks related to its lead abuse-deterrent fentanyl patch is a key step toward commercial...
Quantum BioPharma's Lucid-MS candidate for progressive multiple sclerosis draws a 'Buy' rating from Rodman & Renshaw with an $8.00 price target, highl...
Earth Science Tech's acquisition of Zoolzy LLC aims to boost profit margins, broaden ingredient access, and enter the veterinary market, strengthening...
Italian pharmaceutical company DuLac Farmaceutici is expanding its U.S. presence through a new e-commerce partnership with OneLavi and participation i...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate program into preclinical development, marking a key milestone and expanding it...
Onco-Innovations has signed a letter of intent to potentially license a novel oral small-molecule LAG-3 inhibitor, which could enhance its immuno-onco...
Earth Science Tech's acquisition of Zoolzy LLC aims to enhance its compounding pharmacy operations by securing competitive API pricing and expanding i...
SCHOTT Pharma's updated climate targets, validated by the SBTi, shift focus to absolute Scope 3 emissions reductions, marking a significant step in al...
Helus Pharma's Phase 3 program for HLP003 in major depressive disorder is progressing with enrollment completed and topline data expected in Q4 2026, ...
VERAXA Biotech announced the advancement of its VXA-222 bispecific antibody-drug conjugate program beyond the discovery phase, leveraging OmniAb's ant...
Tonix Pharmaceuticals announced FDA feedback supporting an adaptive Phase 2 field study for its Lyme disease prevention candidate TNX-4800, marking a ...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed key discovery work, moving t...
VERAXA Biotech AG has appointed Christoph Erkel, Ph.D., as chief scientific officer, leveraging his two decades of antibody therapeutics experience to...
NanoViricides announced a $3.8 million registered direct offering with a single institutional investor, providing capital to advance its broad-spectru...
VERAXA Biotech AG appointed Christoph Erkel as Chief Scientific Officer to lead advancement of its proprietary BiTAC(R) platform for cancer therapies ...
VERAXA Biotech AG announced positive Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC-TCE program, reducing development un...
VERAXA Biotech announced Scientific Advice from Germany's Paul-Ehrlich-Institute, validating its dual-targeting BiTAC-TCE platform and supporting its ...
Siegfried appoints Eduardo Montanha as Chief Operating Officer to lead its global manufacturing network, supporting the company's strategy to offer in...
NextPlat Corp acquires a rural Florida pharmacy for $1.5 million to expand PharmcoRx into an underserved market, leveraging same-day delivery and 340B...
Onco-Innovations Limited announced the successful completion of an analytical reference standard program for its lead oncology candidate ONC010, a key...
VERAXA Biotech has initiated cell line development for its lead BiTAC(R) T-cell engager program by partnering with ATUM, marking a key step toward IND...
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by chroni...
VERAXA Biotech provided a corporate and pipeline update highlighting advancement of its proprietary BiTAC platform and growing interest from potential...
VERAXA Biotech announced the start of cell line development for its lead BiTAC T-cell engager program, aiming to reduce off-tumor toxicity in cancer t...
The article highlights that VERAXA Biotech AG's technology platform in antibody-drug conjugates and T-cell engagers places it favorably for potential ...
Ace Therapeutics announces full-spectrum preclinical analgesic drug development services with validated in vivo pain models and integrated research ca...
Medios AG is closing its Aschaffenburg facility and consolidating production to improve efficiency and profitability, affecting 32 employees.
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trials for HLP003 in major depressive disorder, with topline data exp...
Voyageur Pharmaceuticals has hired Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated co...
Knight Therapeutics (TSX: GUD) has fully repaid the $60 million drawn from its revolving credit facility in June 2025 to finance the acquisition of Pa...
Voyageur Pharmaceuticals is evaluating sites in Oklahoma and Texas for a vertically integrated contrast media facility that could reduce costs and sec...
Earth Science Tech Inc. (ETST) has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emph...
Voyageur Pharmaceuticals has submitted a multi-year area-based exploration permit application for its Frances Creek barite project, including a 2,000-...
Voyageur Pharmaceuticals has closed a non-brokered private placement raising $5,005,278.32 to fund FDA licensing for its barium contrast products, reg...
Kairos Pharma announced plans to acquire worldwide rights to Phase 1-ready CL-741, an oral c-MET kinase inhibitor, and provided updates on its lead ca...
